logo-loader
viewAstraZeneca

AstraZeneca shares under pressure after lung cancer setback

AZ’s Imfinzi was paired with tremelimumab, an immune checkpoint blocker, to treat patients with non-small cell lung cancer

1524554194_TuberculosisXray.jpg
As a therapy on its own, Imfinzi showed “a clinically-meaningful reduction in the risk of death”

AstraZeneca PLC (LON:AZN) shares were under early pressure after its combination therapy failed to make a meaningful impact on the disease progression of very ill lung cancer sufferers.

AZ’s Imfinzi was paired with tremelimumab, an immune checkpoint blocker, and given to people who’d received at least two other rounds of different treatment.

READ: US FDA approves AstraZenca’s Tagrisso drug as first-line treatment for lung cancer

Together, the two medications weren’t statistically superior to the standard of care chemotherapy.

The Phase III ARCTIC trial focused on PDL1-low/negative non-small cell lung cancer sufferers.

As a therapy on its own, Imfinzi showed “a clinically-meaningful reduction in the risk of death” compared to chemotherapy, AZ said in a statement.

Chief medical officer Sean Bohen told investors: "While we are disappointed that the combination of Imfinzi plus tremelimumab did not result in a statistically-significant survival benefit in this heavily pre-treated patient population, we are encouraged by the activity of Imfinzi monotherapy observed in this trial and look forward to presenting the full data from the ARCTIC trial at an upcoming medical meeting."

The stock was down 1% at £49.62.

Quick facts: AstraZeneca

Price: 8550 GBX

LSE:AZN
Market: LSE
Market Cap: £112.2 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Directa Plus CEO proud to play role in new Genoa San Giorgio Bridge construction

Directa Plus PLC's (LON:DCTA) Giulio Cesareo speaks to Proactive's Andrew Scott soon after the opening of the new Genoa San Giorgio Bridge which was constructed using Iterchimica's Gipave asphalt supermodifier for its road pavement. It contains graphene and a specific type of...

13 hours, 34 minutes ago

2 min read